{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:17:34Z","timestamp":1789881454019,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.52","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T07:40:57Z","timestamp":1487058057000},"page":"2288-2302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target"],"prefix":"10.1038","volume":"31","author":[{"given":"A","family":"Etxabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Lara-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Cornet-Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ban\u00fas-Mulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Torrente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Risue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"BFleu201752_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453\u2013474.","journal-title":"Blood"},{"key":"BFleu201752_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730\u2013737.","journal-title":"Nat Med"},{"key":"BFleu201752_CR3","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1001\/jama.2010.1862","volume":"304","author":"AJ Gentles","year":"2010","unstructured":"Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA . Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706\u20132715.","journal-title":"JAMA"},{"key":"BFleu201752_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086\u20131093.","journal-title":"Nat Med"},{"key":"BFleu201752_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315\u20131321.","journal-title":"Nat Biotechnol"},{"key":"BFleu201752_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ajh.23404","volume":"88","author":"EH Estey","year":"2013","unstructured":"Estey EH . Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88: 318\u2013327.","journal-title":"Am J Hematol"},{"key":"BFleu201752_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drup.2014.09.001","volume":"17","author":"MA Peters","year":"2014","unstructured":"Peters MA, Walenkamp AM, Kema IP, Meijer C, de Vries EG, Oosting SF . Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. Drug Resist Updat 2014; 17: 96\u2013104.","journal-title":"Drug Resist Updat"},{"key":"BFleu201752_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","volume":"149","author":"E Sachlos","year":"2012","unstructured":"Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149: 1284\u20131297.","journal-title":"Cell"},{"key":"BFleu201752_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","volume":"195","author":"J Hannon","year":"2008","unstructured":"Hannon J, Hoyer D . Molecular biology of 5-HT receptors. Behav Brain Res 2008; 195: 198\u2013213.","journal-title":"Behav Brain Res"},{"key":"BFleu201752_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0014-2999(96)00812-6","volume":"318","author":"LM Vicentini","year":"1996","unstructured":"Vicentini LM, Cattaneo MG, Fesce R . Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells. Eur J Pharmacol 1996; 318: 497\u2013504.","journal-title":"Eur J Pharmacol"},{"issue":"Part 1","key":"BFleu201752_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.juro.2006.06.087","volume":"176","author":"EJ Siddiqui","year":"2006","unstructured":"Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH . The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol 2006; 176 (Part 1): 1648\u20131653.","journal-title":"J Urol"},{"key":"BFleu201752_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1464-410X.2006.06056.x","volume":"97","author":"EJ Siddiqui","year":"2006","unstructured":"Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS . The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int 2006; 97: 634\u2013639.","journal-title":"BJU Int"},{"key":"BFleu201752_CR13","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1158\/0008-5472.CAN-08-2133","volume":"68","author":"G Alpini","year":"2008","unstructured":"Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008; 68: 9184\u20139193.","journal-title":"Cancer Res"},{"key":"BFleu201752_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/BF01209592","volume":"121","author":"W Huhnt","year":"1995","unstructured":"Huhnt W, Lubbe AS . Venules and arterioles in xenotransplanted human colon adenocarcinoma critically constrict with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995; 121: 267\u2013274.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFleu201752_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF01212950","volume":"121","author":"W Huhnt","year":"1995","unstructured":"Huhnt W, Lubbe AS . Growth, microvessel density and tumor cell invasion of human colon adenocarcinoma under repeated treatment with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995; 121: 423\u2013428.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Part 2","key":"BFleu201752_CR16","first-page":"H704","volume":"262","author":"O Stucker","year":"1992","unstructured":"Stucker O, Vicaut E, Teisseire B . Specific response to 5-HT2 agonists by arterioles linked to Meth A tumors in mice. Am J Physiol 1992; 262 (Part 2): H704\u2013H709.","journal-title":"Am J Physiol"},{"key":"BFleu201752_CR17","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.18632\/oncotarget.2016","volume":"5","author":"D Moreno-Martinez","year":"2014","unstructured":"Moreno-Martinez D, Nomdedeu M, Lara-Castillo MC, Etxabe A, Pratcorona M, Tesi N et al. XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget 2014; 5: 4337\u20134346.","journal-title":"Oncotarget"},{"key":"BFleu201752_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1476-5381.1985.tb08948.x","volume":"86","author":"W Feniuk","year":"1985","unstructured":"Feniuk W, Humphrey PP, Perren MJ, Watts AD . A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol 1985; 86: 697\u2013704.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1476-5381.1987.tb16844.x","volume":"90","author":"SJ Ireland","year":"1987","unstructured":"Ireland SJ, Tyers MB . Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 1987; 90: 229\u2013238.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0022-3565(25)23710-7","volume":"234","author":"JA Schuurkes","year":"1985","unstructured":"Schuurkes JA, Van Nueten JM, Van Daele PG, Reyntjens AJ, Janssen PA . Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther 1985; 234: 775\u2013783.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu201752_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791\u2013804.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu201752_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/BF00501854","volume":"274","author":"MA Monachon","year":"1972","unstructured":"Monachon MA, Burkard WP, Jalfre M, Haefely W . Blockade of central 5-hydroxytryptamine receptors by methiothepin. Naunyn Schmiedebergs Arch Pharmacol 1972; 274: 192\u2013197.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFleu201752_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.bjp.0703414","volume":"130","author":"JL Turvill","year":"2000","unstructured":"Turvill JL, Connor P, Farthing MJ . The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br J Pharmacol 2000; 130: 1031\u20131036.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1476-5381.1994.tb14064.x","volume":"111","author":"JD Gale","year":"1994","unstructured":"Gale JD, Grossman CJ, Whitehead JW, Oxford AW, Bunce KT, Humphrey PP . GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br J Pharmacol 1994; 111: 332\u2013338.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0014-2999(88)90212-9","volume":"154","author":"RA Glennon","year":"1988","unstructured":"Glennon RA, Naiman NA, Pierson ME, Titeler M, Lyon RA, Weisberg E . NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol 1988; 154: 339\u2013341.","journal-title":"Eur J Pharmacol"},{"key":"BFleu201752_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/sj.bjp.0702059","volume":"125","author":"JV Selkirk","year":"1998","unstructured":"Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM et al. SB-224289\u2014a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 1998; 125: 202\u2013208.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/PL00005056","volume":"356","author":"GW Price","year":"1997","unstructured":"Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Gothert M et al. SB-216641 and BRL-15572\u2014compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 312\u2013320.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFleu201752_CR28","first-page":"365","volume":"30","author":"LE Arvidsson","year":"1986","unstructured":"Arvidsson LE, Hacksell U, Glennon RA . Recent advances in central 5-hydroxytryptamine receptor agonists and antagonists. Prog Drug Res 1986; 30: 365\u2013471.","journal-title":"Prog Drug Res"},{"key":"BFleu201752_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1476-5381.1986.tb10832.x","volume":"87","author":"HE Connor","year":"1986","unstructured":"Connor HE, Feniuk W, Humphrey PP, Perren MJ . 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol 1986; 87: 417\u2013426.","journal-title":"Br J Pharmacol"},{"key":"BFleu201752_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1748-717X-1-4","volume":"1","author":"S Linder","year":"2006","unstructured":"Linder S, Shoshan MC . Is translational research compatible with preclinical publication strategies? Radiat Oncol 2006; 1: 4.","journal-title":"Radiat Oncol"},{"key":"BFleu201752_CR31","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.4049\/jimmunol.153.7.3276","volume":"153","author":"DE Zhang","year":"1994","unstructured":"Zhang DE, Hetherington CJ, Gonzalez DA, Chen HM, Tenen DG . Regulation of CD14 expression during monocytic differentiation induced with 1 alpha,25-dihydroxyvitamin D3. J Immunol 1994; 153: 3276\u20133284.","journal-title":"J Immunol"},{"key":"BFleu201752_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1078\/0171-9335-00219","volume":"81","author":"I Prudovsky","year":"2002","unstructured":"Prudovsky I, Popov K, Akimov S, Serov S, Zelenin A, Meinhardt G et al. Antisense CD11b integrin inhibits the development of a differentiated monocyte\/macrophage phenotype in human leukemia cells. Eur J Cell Biol 2002; 81: 36\u201342.","journal-title":"Eur J Cell Biol"},{"key":"BFleu201752_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer D, Hannon JP, Martin GR . Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533\u2013554.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFleu201752_CR34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972\u2013980.","journal-title":"Blood"},{"key":"BFleu201752_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.leu.2403653","volume":"19","author":"VL Grandage","year":"2005","unstructured":"Grandage VL, Gale RE, Linch DC, Khwaja A . PI3-kinase\/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586\u2013594.","journal-title":"Leukemia"},{"key":"BFleu201752_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2174\/1568011054866937","volume":"5","author":"F Stauffer","year":"2005","unstructured":"Stauffer F, Holzer P, Garcia-Echeverria C . Blocking the PI3K\/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents 2005; 5: 449\u2013462.","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"BFleu201752_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.leu.2402874","volume":"17","author":"YH Min","year":"2003","unstructured":"Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. Constitutive phosphorylation of Akt\/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003; 17: 995\u2013997.","journal-title":"Leukemia"},{"key":"BFleu201752_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1523\/JNEUROSCI.02-03-00376.1982","volume":"2","author":"MJ Schmidt","year":"1982","unstructured":"Schmidt MJ, Sawyer BD, Perry KW, Fuller RW, Foreman MM, Ghetti B . Dopamine deficiency in the weaver mutant mouse. J Neurosci 1982; 2: 376\u2013380.","journal-title":"J Neurosci"},{"key":"BFleu201752_CR39","first-page":"357","volume":"55","author":"OT Ginawi","year":"2004","unstructured":"Ginawi OT, Al-Majed AA, Al-Suwailem AK, El-Hadiyah TM . Involvement of some 5-HT receptors in methamphetamine-induced locomotor activity in mice. J Physiol Pharmacol 2004; 55: 357\u2013369.","journal-title":"J Physiol Pharmacol"},{"key":"BFleu201752_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/1471-2458-12-439","volume":"12","author":"SC Walpole","year":"2012","unstructured":"Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I . The weight of nations: an estimation of adult human biomass. BMC Public Health 2012; 12: 439.","journal-title":"BMC Public Health"},{"key":"BFleu201752_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1182\/blood-2012-02-409888","volume":"120","author":"BZ Carter","year":"2012","unstructured":"Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR et al. Survivin is highly expressed in CD34(+)38(\u2212) leukemic stem\/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012; 120: 173\u2013180.","journal-title":"Blood"},{"key":"BFleu201752_CR42","doi-asserted-by":"publisher","first-page":"946936","DOI":"10.1155\/2011\/946936","volume":"2011","author":"S Fukuda","year":"2011","unstructured":"Fukuda S, Abe M, Onishi C, Taketani T, Purevsuren J, Yamaguchi S et al. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol 2011; 2011: 946936.","journal-title":"J Oncol"},{"key":"BFleu201752_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ijc.21995","volume":"119","author":"M Wagner","year":"2006","unstructured":"Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B, Tamm I . In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006; 119: 1291\u20131297.","journal-title":"Int J Cancer"},{"issue":"Part 2","key":"BFleu201752_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1042\/bj3430435","volume":"343","author":"PJ Pauwels","year":"1999","unstructured":"Pauwels PJ, Gouble A, Wurch T . Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions. Biochem J 1999; 343 (Part 2): 435\u2013442.","journal-title":"Biochem J"},{"key":"BFleu201752_CR45","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00018-015-2108-7","volume":"73","author":"Y Hu","year":"2016","unstructured":"Hu Y, Li S . Survival regulation of leukemia stem cells. Cell Mol Life Sci 2016; 73: 1039\u20131050.","journal-title":"Cell Mol Life Sci"},{"key":"BFleu201752_CR46","doi-asserted-by":"publisher","first-page":"23239","DOI":"10.18632\/oncotarget.8096","volume":"7","author":"JM Cornet-Masana","year":"2016","unstructured":"Cornet-Masana JM, Moreno-Martinez D, Lara-Castillo MC, Nomdedeu M, Etxabe A, Tesi N et al. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. Oncotarget 2016; 7: 23239\u201323250.","journal-title":"Oncotarget"},{"key":"BFleu201752_CR47","first-page":"780","volume":"8","author":"M Flasshove","year":"1994","unstructured":"Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994; 8: 780\u2013785.","journal-title":"Leukemia"},{"key":"BFleu201752_CR48","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","volume":"117","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002; 117: 860\u2013868.","journal-title":"Br J Haematol"},{"key":"BFleu201752_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-015-0326-0","volume":"14","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Chen HX, Zhou SY, Wang SX, Zheng K, Xu DD et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer 2015; 14: 56.","journal-title":"Mol Cancer"},{"key":"BFleu201752_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0065-230X(08)60912-4","volume":"35","author":"MC Berenbaum","year":"1981","unstructured":"Berenbaum MC . Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 269\u2013335.","journal-title":"Adv Cancer Res"},{"key":"BFleu201752_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BFleu201752_CR52","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/annonc\/mdp309","volume":"21","author":"D Pulte","year":"2010","unstructured":"Pulte D, Gondos A, Brenner H . Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol 2010; 21: 335\u2013341.","journal-title":"Ann Oncol"},{"key":"BFleu201752_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/pros.10374","volume":"59","author":"N Dizeyi","year":"2004","unstructured":"Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004; 59: 328\u2013336.","journal-title":"Prostate"},{"key":"BFleu201752_CR54","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/hep.23441","volume":"51","author":"C Soll","year":"2010","unstructured":"Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010; 51: 1244\u20131254.","journal-title":"Hepatology"},{"key":"BFleu201752_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-2187-2-2","volume":"2","author":"DC New","year":"2007","unstructured":"New DC, Wong YH . Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2007; 2: 2.","journal-title":"J Mol Signal"},{"key":"BFleu201752_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND . How to calculate sample size in animal studies? J Pharmacol Pharmacother 2013; 4: 303\u2013306.","journal-title":"J Pharmacol Pharmacother"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201752","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu201752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T09:39:15Z","timestamp":1749980355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu201752"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.52","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]},"assertion":[{"value":"21 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The results presented in this paper have been patented. RMR is a shareholder of Leukos Biotech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}